

Emad A Rakha

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4793805/emad-a-rakha-publications-by-year.pdf>

Version: 2023-09-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

410
papers

20,586
citations

60
h-index

132
g-index

445
ext. papers

24,677
ext. citations

6.1
avg, IF

6.65
L-index

#	Paper	IF	Citations
410	Quantifying Lymphatic Vessel Density in Human Tissue Samples.. <i>Methods in Molecular Biology</i> , 2022 , 2441, 183-189	1.4	
409	Ubiquitin-conjugating enzyme 2C (UBE2C) is a poor prognostic biomarker in invasive breast cancer.. <i>Breast Cancer Research and Treatment</i> , 2022 , 192, 529	4.4	1
408	Association of L-type amino acid transporter 1 (LAT1) with the immune system and prognosis in invasive breast cancer.. <i>Scientific Reports</i> , 2022 , 12, 2742	4.9	2
407	Applications and implications of whole-slide imaging in breast pathology. <i>Diagnostic Histopathology</i> , 2022 , 28, 149-155	0.7	
406	Automated quality assessment of large digitised histology cohorts by artificial intelligence.. <i>Scientific Reports</i> , 2022 , 12, 5002	4.9	1
405	Standardization of the tumor-stroma ratio scoring method for breast cancer research.. <i>Breast Cancer Research and Treatment</i> , 2022 , 193, 545	4.4	2
404	Upregulation of Cyclin B2 () in breast cancer contributes to the development of lymphovascular invasion.. <i>American Journal of Cancer Research</i> , 2022 , 12, 469-489	4.4	
403	Epigenome erosion and SOX10 drive neural crest phenotypic mimicry in triple-negative breast cancer.. <i>Npj Breast Cancer</i> , 2022 , 8, 57	7.8	1
402	Lessons from a breast cell annotation competition series for school pupils.. <i>Scientific Reports</i> , 2022 , 12, 7792	4.9	
401	Aurora Kinase A Is an Independent Predictor of Invasive Recurrence in Breast Ductal Carcinoma in situ.. <i>Pathobiology</i> , 2022 , 1-11	3.6	1
400	SlideGraph+: Whole Slide Image Level Graphs to Predict HER2 Status in Breast Cancer. <i>Medical Image Analysis</i> , 2022 , 102486	15.4	0
399	Digital pathology and artificial intelligence will be key to supporting clinical and academic cellular pathology through COVID-19 and future crises: the PathLAKE consortium perspective. <i>Journal of Clinical Pathology</i> , 2021 , 74, 443-447	3.9	28
398	Intra-operative assessment of sentinel lymph nodes for breast cancer surgery: An update. <i>Surgical Oncology</i> , 2021 , 40, 101678	2.5	0
397	Triple-Negative Breast Cancer Histological Subtypes with a Favourable Prognosis. <i>Cancers</i> , 2021 , 13,	6.6	6
396	Untangling the clinicopathological significance of MRE11-RAD50-NBS1 complex in sporadic breast cancers. <i>Npj Breast Cancer</i> , 2021 , 7, 143	7.8	1
395	Nuclear morphology in breast lesions: refining its assessment to improve diagnostic concordance. <i>Histopathology</i> , 2021 , 80, 515	7.3	2
394	Flower lose, a cell fitness marker, predicts COVID-19 prognosis. <i>EMBO Molecular Medicine</i> , 2021 , 13, e13714		0

393	Prognostic significance of receptor expression discordance between primary and recurrent breast cancers: a meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2021 , 1	4.4	0
392	Current and future applications of artificial intelligence in pathology: a clinical perspective. <i>Journal of Clinical Pathology</i> , 2021 , 74, 409-414	3.9	13
391	Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patients undergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio ≥ 0 , HER2 copy number). <i>British Journal of Cancer</i> , 2021 , 124, 1836-1842	8.7	2
390	Molecular disruption of DNA polymerase β for platinum sensitisation and synthetic lethality in epithelial ovarian cancers. <i>Oncogene</i> , 2021 , 40, 2496-2508	9.2	2
389	RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer. <i>Breast Cancer Research</i> , 2021 , 23, 42	8.3	3
388	FEN1 Blockade for Platinum Chemo-Sensitization and Synthetic Lethality in Epithelial Ovarian Cancers. <i>Cancers</i> , 2021 , 13,	6.6	5
387	PP1, PKA and DARPP-32 in breast cancer: A retrospective assessment of protein and mRNA expression. <i>Journal of Cellular and Molecular Medicine</i> , 2021 , 25, 5015-5024	5.6	1
386	Artificial intelligence for advance requesting of immunohistochemistry in diagnostically uncertain prostate biopsies. <i>Modern Pathology</i> , 2021 , 34, 1780-1794	9.8	4
385	Artificial intelligence grading of breast cancer: a promising method to refine prognostic classification for management precision. <i>Histopathology</i> , 2021 , 79, 187-199	7.3	2
384	The prognostic significance of Flap Endonuclease 1 (FEN1) in breast ductal carcinoma in situ. <i>Breast Cancer Research and Treatment</i> , 2021 , 188, 53-63	4.4	0
383	Adenomyoepithelioma of the breast: a proposal for classification. <i>Histopathology</i> , 2021 , 79, 465-479	7.3	10
382	The Mammalian Ecdysoless Protein Interacts with RNA Helicase DDX39A To Regulate Nuclear mRNA Export. <i>Molecular and Cellular Biology</i> , 2021 , 41, e0010321	4.8	0
381	Diagnostic concordance of phyllodes tumour of the breast. <i>Histopathology</i> , 2021 , 79, 607-618	7.3	0
380	Spindle cell lesions of the breast: a diagnostic approach. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021 , 1	5.1	6
379	Determining breast cancer biomarker status and associated morphological features using deep learning. <i>Communications Medicine</i> , 2021 , 1,		7
378	SLC1A5 co-expression with TALDO1 associates with endocrine therapy failure in estrogen receptor-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021 , 189, 317-331	4.4	1
377	New Advances in Molecular Breast Cancer Pathology. <i>Seminars in Cancer Biology</i> , 2021 , 72, 102-113	12.7	13
376	Werner Syndrome Protein Expression in Breast Cancer. <i>Clinical Breast Cancer</i> , 2021 , 21, 57-73.e7	3	3

375	Increased expression of glutamine transporter SNAT2/SLC38A2 promotes glutamine dependence and oxidative stress resistance, and is associated with worse prognosis in triple-negative breast cancer. <i>British Journal of Cancer</i> , 2021 , 124, 494-505	8.7	13
374	The prognostic significance of interferon-stimulated gene 15 (ISG15) in invasive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021 , 185, 293-305	4.4	11
373	Nucleolar protein 10 (NOP10) predicts poor prognosis in invasive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021 , 185, 615-627	4.4	6
372	Metaplastic carcinomas of the breast without evidence of epithelial differentiation: a diagnostic approach for management. <i>Histopathology</i> , 2021 , 78, 759-771	7.3	3
371	Centrosome amplification: a quantifiable cancer cell trait with prognostic value in solid malignancies. <i>Cancer and Metastasis Reviews</i> , 2021 , 40, 319-339	9.6	4
370	Ligase 1 is a predictor of platinum resistance and its blockade is synthetically lethal in XRCC1 deficient epithelial ovarian cancers. <i>Theranostics</i> , 2021 , 11, 8350-8361	12.1	1
369	Clinicopathological and Functional Evaluation Reveal NBS1 as a Predictor of Platinum Resistance in Epithelial Ovarian Cancers. <i>Biomedicines</i> , 2021 , 9,	4.8	2
368	Combined total internal reflection AF spectral-imaging and Raman spectroscopy for fast assessment of surgical margins during breast cancer surgery. <i>Biomedical Optics Express</i> , 2021 , 12, 940-954	3.5	4
367	Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer. <i>Modern Pathology</i> , 2021 , 34, 1271-1281	9.8	12
366	Correlations of morphological features and surgical management with clinical outcome in a multicentre study of 241 phyllodes tumours of the breast. <i>Histopathology</i> , 2021 , 78, 871-881	7.3	2
365	The Biological and Clinical Significance of Glutaminase in Luminal Breast Cancer. <i>Cancers</i> , 2021 , 13,	6.6	3
364	Oestrogen-regulated protein SLC39A6: a biomarker of good prognosis in luminal breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021 , 189, 621-630	4.4	1
363	The frequency and clinical significance of DNA polymerase beta (POLB) expression in breast ductal carcinoma in situ (DCIS). <i>Breast Cancer Research and Treatment</i> , 2021 , 190, 39-51	4.4	
362	Predicting the Economic Impact of the COVID-19 Pandemic in the United Kingdom Using Time-Series Mining. <i>Economies</i> , 2021 , 9, 137	2	3
361	Visual assessment of mitotic figures in breast cancer: a comparative study between light microscopy and whole slide images. <i>Histopathology</i> , 2021 , 79, 913-925	7.3	1
360	Assessment of proliferation in breast cancer: cell cycle or mitosis? An observational study. <i>Histopathology</i> , 2021 , 79, 1087-1098	7.3	0
359	L1-Regularized Neural Ranking for Risk Stratification and Its Application to Prediction of Time to Distant Metastasis in Luminal Node Negative Chemotherapy Naïve Breast Cancer Patients. <i>Communications in Computer and Information Science</i> , 2021 , 390-400	0.3	
358	Digital Technology in Diagnostic Breast Pathology and Immunohistochemistry.. <i>Pathobiology</i> , 2021 , 1-9	3.6	1

357	Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020 , 181, 541-551	4.4	6
356	Retrospective assessment of cyclin-dependent kinase 5 mRNA and protein expression and its association with patient survival in breast cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2020 , 24, 6263-6271	5.6	4
355	The prognostic significance of ALDH1A1 expression in early invasive breast cancer. <i>Histopathology</i> , 2020 , 77, 437-448	7.3	10
354	A novel prognostic two-gene signature for triple negative breast cancer. <i>Modern Pathology</i> , 2020 , 33, 2208-2220	9.8	13
353	Histological clues to the diagnosis of metastasis to the breast from extramammary malignancies. <i>Histopathology</i> , 2020 , 77, 303-313	7.3	6
352	PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer. <i>BMC Cancer</i> , 2020 , 20, 425	4.8	5
351	The prognostic significance of BMI1 expression in invasive breast cancer is dependent on its molecular subtypes. <i>Breast Cancer Research and Treatment</i> , 2020 , 182, 581-589	4.4	5
350	Pleomorphic adenomas and mucoepidermoid carcinomas of the breast are underpinned by fusion genes. <i>Npj Breast Cancer</i> , 2020 , 6, 20	7.8	12
349	Integrated Analysis of Key Differentially Expressed Genes Identifies DBN1 as a Predictive Marker of Response to Endocrine Therapy in Luminal Breast Cancer. <i>Cancers</i> , 2020 , 12,	6.6	3
348	The prognostic significance of immune microenvironment in breast ductal carcinoma in situ. <i>British Journal of Cancer</i> , 2020 , 122, 1496-1506	8.7	15
347	The genetic architecture of breast papillary lesions as a predictor of progression to carcinoma. <i>Npj Breast Cancer</i> , 2020 , 6, 9	7.8	13
346	The solute carrier SLC7A8 is a marker of favourable prognosis in ER-positive low proliferative invasive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020 , 181, 1-12	4.4	3
345	Co-Expression Effect of SLC7A5/SLC3A2 to Predict Response to Endocrine Therapy in Oestrogen-Receptor-Positive Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	12
344	Feasibility of integrated high-wavenumber Raman imaging and fingerprint Raman spectroscopy for fast margin assessment in breast cancer surgery. <i>Journal of Raman Spectroscopy</i> , 2020 , 51, 1986-1995	2.3	8
343	Molecular Complexity of Lymphovascular Invasion: The Role of Cell Migration in Breast Cancer as a Prototype. <i>Pathobiology</i> , 2020 , 87, 218-231	3.6	8
342	Visual histological assessment of morphological features reflects the underlying molecular profile in invasive breast cancer: a morphomolecular study. <i>Histopathology</i> , 2020 , 77, 631-645	7.3	4
341	A Quantitative Centrosomal Amplification Score Predicts Local Recurrence of Ductal Carcinoma. <i>Clinical Cancer Research</i> , 2020 , 26, 2898-2907	12.9	4
340	Combined HER3-EGFR score in triple-negative breast cancer provides prognostic and predictive significance superior to individual biomarkers. <i>Scientific Reports</i> , 2020 , 10, 3009	4.9	11

339	PIK3C β expression by fibroblasts promotes triple-negative breast cancer progression. <i>Journal of Clinical Investigation</i> , 2020 , 130, 3188-3204	15.9	13
338	XRCC1 deficient triple negative breast cancers are sensitive to ATR, ATM and Wee1 inhibitor either alone or in combination with olaparib. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920974201 ³	5.4	13
337	RAD50 deficiency is a predictor of platinum sensitivity in sporadic epithelial ovarian cancers.. <i>Molecular Biomedicine</i> , 2020 , 1, 19	3.1	3
336	Breast Pathology. <i>Encyclopedia of Pathology</i> , 2020 , 384-387	0	
335	The ITIM-Containing Receptor: Leukocyte-Associated Immunoglobulin-Like Receptor-1 (LAIR-1) Modulates Immune Response and Confers Poor Prognosis in Invasive Breast Carcinoma. <i>Cancers</i> , 2020 , 13,	6.6	3
334	Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival. <i>Breast Cancer Research and Treatment</i> , 2020 , 182, 267-282	4.4	12
333	Clinicopathological significance of lipocalin 2 nuclear expression in invasive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020 , 179, 557-564	4.4	5
332	Prognostic significance of KN motif and ankyrin repeat domains 1 (KANK1) in invasive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020 , 179, 349-357	4.4	14
331	Immunohistochemical assessment of HRAS Q61R mutations in breast adenomyoepitheliomas. <i>Histopathology</i> , 2020 , 76, 865-874	7.3	13
330	Artificial intelligence in digital breast pathology: Techniques and applications. <i>Breast</i> , 2020 , 49, 267-273	3.6	41
329	Prognostic significance of nucleolar assessment in invasive breast cancer. <i>Histopathology</i> , 2020 , 76, 671-684	6.8	7
328	Enhanced glutamine uptake influences composition of immune cell infiltrates in breast cancer. <i>British Journal of Cancer</i> , 2020 , 122, 94-101	8.7	13
327	The prognostic value of the tumor-stroma ratio is most discriminative in patients with grade III or triple-negative breast cancer. <i>International Journal of Cancer</i> , 2020 , 146, 2296-2304	7.5	18
326	Immunohistochemical analysis of IDH2 R172 hotspot mutations in breast papillary neoplasms: applications in the diagnosis of tall cell carcinoma with reverse polarity. <i>Modern Pathology</i> , 2020 , 33, 1056-1064	9.8	21
325	Digital pathology for primary diagnosis of screen-detected breast lesions: Experimental data, validation and experience from four centres. <i>Histopathology</i> , 2020 , 76, 968-975	7.3	9
324	IL6/STAT3 Signaling Hijacks Estrogen Receptor Enhancers to Drive Breast Cancer Metastasis. <i>Cancer Cell</i> , 2020 , 38, 412-423.e9	24.3	46
323	The clinical significance of oestrogen receptor expression in breast ductal carcinoma in situ. <i>British Journal of Cancer</i> , 2020 , 123, 1513-1520	8.7	3
322	Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets. <i>Breast Cancer Research</i> , 2020 , 22, 85	8.3	11

321	The nucleolar-related protein Dyskerin pseudouridine synthase 1 (DKC1) predicts poor prognosis in breast cancer. <i>British Journal of Cancer</i> , 2020 , 123, 1543-1552	8.7	8
320	The intra-tumoural stroma in patients with breast cancer increases with age. <i>Breast Cancer Research and Treatment</i> , 2020 , 179, 37-45	4.4	4
319	The role of glutaminase in cancer. <i>Histopathology</i> , 2020 , 76, 498-508	7.3	39
318	PARP1 blockade is synthetically lethal in XRCC1 deficient sporadic epithelial ovarian cancers. <i>Cancer Letters</i> , 2020 , 469, 124-133	9.9	13
317	The prognostic significance of wild-type isocitrate dehydrogenase 2 (IDH2) in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020 , 179, 79-90	4.4	8
316	Prognostic significance of cathepsin V (CTSV/CTSL2) in breast ductal carcinoma in situ. <i>Journal of Clinical Pathology</i> , 2020 , 73, 76-82	3.9	23
315	Predicting Metastasis Risk in Pancreatic Neuroendocrine Tumors Using Deep Learning Image Analysis. <i>Frontiers in Oncology</i> , 2020 , 10, 593211	5.3	3
314	CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy. <i>Breast Cancer Research and Treatment</i> , 2019 , 178, 535-544	4.4	17
313	Retinoid X receptor gamma (RXRG) is an independent prognostic biomarker in ER-positive invasive breast cancer. <i>British Journal of Cancer</i> , 2019 , 121, 776-785	8.7	7
312	Assessment of and rearrangements in breast adenomyoepitheliomas. <i>Npj Breast Cancer</i> , 2019 , 5, 6	7.8	15
311	The combined expression of solute carriers is associated with a poor prognosis in highly proliferative ER+ breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019 , 175, 27-38	4.4	14
310	Collagen (XI) alpha-1 chain is an independent prognostic factor in breast ductal carcinoma in situ. <i>Modern Pathology</i> , 2019 , 32, 1460-1472	9.8	13
309	Geometric characteristics of collagen have independent prognostic significance in breast ductal carcinoma in situ: an image analysis study. <i>Modern Pathology</i> , 2019 , 32, 1473-1485	9.8	6
308	Metadherin: A Therapeutic Target in Multiple Cancers. <i>Frontiers in Oncology</i> , 2019 , 9, 349	5.3	28
307	A key genomic subtype associated with lymphovascular invasion in invasive breast cancer. <i>British Journal of Cancer</i> , 2019 , 120, 1129-1136	8.7	12
306	Combining clustering and classification ensembles: A novel pipeline to identify breast cancer profiles. <i>Artificial Intelligence in Medicine</i> , 2019 , 97, 27-37	7.4	18
305	The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ: a large study from a single institution. <i>British Journal of Cancer</i> , 2019 , 120, 1075-1082	8.7	15
304	Atypical ductal hyperplasia is a multipotent precursor of breast carcinoma. <i>Journal of Pathology</i> , 2019 , 248, 326-338	9.4	12

303	Utility of ankyrin 3 as a prognostic marker in androgen-receptor-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019 , 176, 63-73	4.4	4
302	ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancers. <i>Gynecologic Oncology</i> , 2019 , 153, 416-424	4.9	13
301	The prognostic significance of lysosomal protective protein (cathepsin A) in breast ductal carcinoma in situ. <i>Histopathology</i> , 2019 , 74, 1025-1035	7.3	11
300	The role of PIP5K1 β /pAKT and targeted inhibition of growth of subtypes of breast cancer using PIP5K1 β inhibitor. <i>Oncogene</i> , 2019 , 38, 375-389	9.2	12
299	Machine learning-based prediction of breast cancer growth rate in vivo. <i>British Journal of Cancer</i> , 2019 , 121, 497-504	8.7	2
298	ERCC1 Is a Predictor of Anthracycline Resistance and Taxane Sensitivity in Early Stage or Locally Advanced Breast Cancers. <i>Cancers</i> , 2019 , 11,	6.6	6
297	Surgical management of ductal carcinoma in situ of the breast: A large retrospective study from a single institution. <i>Breast Journal</i> , 2019 , 25, 1143-1153	1.2	3
296	Whole-exome sequencing and RNA sequencing analyses of acinic cell carcinomas of the breast. <i>Histopathology</i> , 2019 , 75, 931-937	7.3	9
295	A whole slide image-based machine learning approach to predict ductal carcinoma in situ (DCIS) recurrence risk. <i>Breast Cancer Research</i> , 2019 , 21, 83	8.3	22
294	ATM Regulated PTEN Degradation Is XIAP E3 Ubiquitin Ligase Mediated in p85 β Deficient Cancer Cells and Influence Platinum Sensitivity. <i>Cells</i> , 2019 , 8,	7.9	9
293	SHON expression predicts response and relapse risk of breast cancer patients after anthracycline-based combination chemotherapy or tamoxifen treatment. <i>British Journal of Cancer</i> , 2019 , 120, 728-745	8.7	2
292	Clinicopathological significance of ataxia telangiectasia-mutated (ATM) kinase and ataxia telangiectasia-mutated and Rad3-related (ATR) kinase in MYC overexpressed breast cancers. <i>Breast Cancer Research and Treatment</i> , 2019 , 175, 105-115	4.4	7
291	The molecular mechanisms underlying reduced E-cadherin expression in invasive ductal carcinoma of the breast: high throughput analysis of large cohorts. <i>Modern Pathology</i> , 2019 , 32, 967-976	9.8	17
290	Dopamine and cAMP-regulated phosphoprotein 32 kDa (DARPP-32) and survival in breast cancer: a retrospective analysis of protein and mRNA expression. <i>Scientific Reports</i> , 2019 , 9, 16987	4.9	5
289	Outcome of radial scar/complex sclerosing lesion associated with epithelial proliferations with atypia diagnosed on breast core biopsy: results from a multicentric UK-based study. <i>Journal of Clinical Pathology</i> , 2019 , 72, 800-804	3.9	5
288	Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019 , 174, 387-399	4.4	33
287	Connexin 43 is an independent predictor of patient outcome in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2019 , 174, 93-102	4.4	20
286	Legumain is an independent predictor for invasive recurrence in breast ductal carcinoma in situ. <i>Modern Pathology</i> , 2019 , 32, 639-649	9.8	9

285	Glutamate dehydrogenase (GLUD1) expression in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019 , 174, 79-91	4.4	16
284	Breast Tumours Resembling the Tall Cell Variant of Thyroid Papillary Carcinoma: Are They Part of the Papillary Carcinoma Spectrum or a Distinct Entity?. <i>Pathobiology</i> , 2019 , 86, 83-91	3.6	6
283	Kinesin family member-18A (KIF18A) is a predictive biomarker of poor benefit from endocrine therapy in early ER+ breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019 , 173, 93-102	4.4	12
282	Immune Infiltration in Invasive Lobular Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2018 , 110, 768-776	9.7	55
281	Loss of the Nuclear Pool of Ubiquitin Ligase CHIP/STUB1 in Breast Cancer Unleashes the MZF1-Cathepsin Pro-oncogenic Program. <i>Cancer Research</i> , 2018 , 78, 2524-2535	10.1	20
280	Solid papillary breast carcinomas resembling the tall cell variant of papillary thyroid neoplasms (solid papillary carcinomas with reverse polarity) harbour recurrent mutations affecting IDH2 and PIK3CA: a validation cohort. <i>Histopathology</i> , 2018 , 73, 339-344	7.3	28
279	Current issues with luminal subtype classification in terms of prediction of benefit from endocrine therapy in early breast cancer. <i>Histopathology</i> , 2018 , 73, 545-558	7.3	12
278	Clinical and biological roles of Kelch-like family member 7 in breast cancer: a marker of poor prognosis. <i>Breast Cancer Research and Treatment</i> , 2018 , 170, 525-533	4.4	9
277	BQ323636.1, a Novel Splice Variant to 2, as a Predictor for Tamoxifen-Resistant Breast Cancer. <i>Clinical Cancer Research</i> , 2018 , 24, 3681-3691	12.9	12
276	Tumour Heterogeneity of Breast Cancer: From Morphology to Personalised Medicine. <i>Pathobiology</i> , 2018 , 85, 23-34	3.6	45
275	Targeting ataxia telangiectasia-mutated- and Rad3-related kinase (ATR) in PTEN-deficient breast cancers for personalized therapy. <i>Breast Cancer Research and Treatment</i> , 2018 , 169, 277-286	4.4	10
274	IL-6 and IL-10 are associated with good prognosis in early stage invasive breast cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2018 , 67, 537-549	7.4	40
273	High nuclear MSK1 is associated with longer survival in breast cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018 , 144, 509-517	4.9	9
272	Breast cancer intratumour heterogeneity: current status and clinical implications. <i>Histopathology</i> , 2018 , 73, 717-731	7.3	21
271	Diagnostic concordance of reporting lymphovascular invasion in breast cancer. <i>Journal of Clinical Pathology</i> , 2018 , 71, 802-805	3.9	8
270	Mediator complex (MED) 7: a biomarker associated with good prognosis in invasive breast cancer, especially ER+ luminal subtypes. <i>British Journal of Cancer</i> , 2018 , 118, 1142-1151	8.7	6
269	The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypes. <i>British Journal of Cancer</i> , 2018 , 118, 1115-1122	8.7	23
268	Prognostic significance of tumor-infiltrating lymphocytes in ductal carcinoma in situ of the breast. <i>Modern Pathology</i> , 2018 , 31, 1226-1236	9.8	40

267	Breast cancer histologic grading using digital microscopy: concordance and outcome association. <i>Journal of Clinical Pathology</i> , 2018 , 71, 680-686	3.9	20
266	Checkpoint Kinase 1 Expression Predicts Poor Prognosis in Nigerian Breast Cancer Patients. <i>Molecular Diagnosis and Therapy</i> , 2018 , 22, 79-90	4.5	8
265	Thioredoxin-interacting protein is an independent risk stratifier for breast ductal carcinoma in situ. <i>Modern Pathology</i> , 2018 , 31, 1807-1815	9.8	21
264	Saccharomyces cerevisiae-like 1 (SEC14L1) is a prognostic factor in breast cancer associated with lymphovascular invasion. <i>Modern Pathology</i> , 2018 , 31, 1675-1682	9.8	7
263	Intra-operative spectroscopic assessment of surgical margins during breast conserving surgery. <i>Breast Cancer Research</i> , 2018 , 20, 69	8.3	54
262	Clinicopathological and prognostic significance of Ras association and pleckstrin homology domains 1 (RAPH1) in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018 , 172, 61-68	4.4	4
261	Eighth Edition Cancer Staging Manual of Breast Cancer by the American Joint Committee on Cancer: are the new changes to improve staging or a treatment decision tool?. <i>Journal of Clinical Pathology</i> , 2018 , 71, 1028-1029	3.9	3
260	Impact of breast cancer grade discordance on prediction of outcome. <i>Histopathology</i> , 2018 , 73, 904-915	7.3	15
259	Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas. <i>Nature Communications</i> , 2018 , 9, 1816	17.4	82
258	The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours. <i>Breast Cancer Research</i> , 2018 , 20, 21	8.3	58
257	Atypical ductal hyperplasia: update on diagnosis, management, and molecular landscape. <i>Breast Cancer Research</i> , 2018 , 20, 39	8.3	21
256	A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. <i>Modern Pathology</i> , 2018 , 31, 1770-1786	9.8	428
255	Inhibition of HER2 Increases JAGGED1-dependent Breast Cancer Stem Cells: Role for Membrane JAGGED1. <i>Clinical Cancer Research</i> , 2018 , 24, 4566-4578	12.9	24
254	The relationship of CDK18 expression in breast cancer to clinicopathological parameters and therapeutic response. <i>Oncotarget</i> , 2018 , 9, 29508-29524	3.3	4
253	MYC regulation of glutamine-proline regulatory axis is key in luminal B breast cancer. <i>British Journal of Cancer</i> , 2018 , 118, 258-265	8.7	47
252	Diagnostic challenges in papillary lesions of the breast. <i>Pathology</i> , 2018 , 50, 100-110	1.6	25
251	Invasion in breast lesions: the role of the epithelial-stroma barrier. <i>Histopathology</i> , 2018 , 72, 1075-1083	7.3	13
250	Altered glutamine metabolism in breast cancer; subtype dependencies and alternative adaptations. <i>Histopathology</i> , 2018 , 72, 183-190	7.3	33

249	Panoptic Overview of Triple-Negative Breast Cancer in Nigeria: Current Challenges and Promising Global Initiatives. <i>Journal of Global Oncology</i> , 2018 , 4, 1-20	2.6	4
248	Low expression of G protein-coupled oestrogen receptor 1 (GPER) is associated with adverse survival of breast cancer patients. <i>Oncotarget</i> , 2018 , 9, 25946-25956	3.3	25
247	The effect of human placental chorionic villi derived mesenchymal stem cell on triple-negative breast cancer hallmarks. <i>PLoS ONE</i> , 2018 , 13, e0207593	3.7	7
246	Prolyl-4-hydroxylase β subunit 2 (P4HA2) expression is a predictor of poor outcome in breast ductal carcinoma in situ (DCIS). <i>British Journal of Cancer</i> , 2018 , 119, 1518-1526	8.7	21
245	Targeting PARP1 in XRCC1-Deficient Sporadic Invasive Breast Cancer or Preinvasive Ductal Carcinoma Induces Synthetic Lethality and Chemoprevention. <i>Cancer Research</i> , 2018 , 78, 6818-6827	10.1	18
244	Co-expression of nuclear P38 and hormone receptors is prognostic of good long-term clinical outcome in primary breast cancer and is linked to upregulation of DNA repair. <i>BMC Cancer</i> , 2018 , 18, 1027	4.8	3
243	Loss-of-function mutations in ATP6AP1 and ATP6AP2 in granular cell tumors. <i>Nature Communications</i> , 2018 , 9, 3533	17.4	60
242	Heterogeneity of tumour-infiltrating lymphocytes in breast cancer and its prognostic significance. <i>Histopathology</i> , 2018 , 73, 887-896	7.3	38
241	Clinicopathological and molecular characteristics of Ku 70/80 expression in Nigerian breast cancer and its potential therapeutic implications. <i>Pathology Research and Practice</i> , 2017 , 213, 27-33	3.4	3
240	Amplified centrosomes and mitotic index display poor concordance between patient tumors and cultured cancer cells. <i>Scientific Reports</i> , 2017 , 7, 43984	4.9	12
239	Androgen dependent mechanisms of pro-angiogenic networks in placental and tumor development. <i>Placenta</i> , 2017 , 56, 79-85	3.4	7
238	Prognostic stratification of oestrogen receptor-positive HER2-negative lymph node-negative class of breast cancer. <i>Histopathology</i> , 2017 , 70, 622-631	7.3	18
237	Clinical Impact of Tumor DNA Repair Expression and T-cell Infiltration in Breast Cancers. <i>Cancer Immunology Research</i> , 2017 , 5, 292-299	12.5	40
236	Review of the national external quality assessment (EQA) scheme for breast pathology in the UK. <i>Journal of Clinical Pathology</i> , 2017 , 70, 51-57	3.9	28
235	Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections. <i>Breast Cancer Research and Treatment</i> , 2017 , 164, 341-348	4.4	33
234	Phenotypic characterisation of breast cancer: the role of CDC42. <i>Breast Cancer Research and Treatment</i> , 2017 , 164, 317-325	4.4	18
233	Chemokine (C-C motif) receptor 7 (CCR7) associates with the tumour immune microenvironment but not progression in invasive breast carcinoma. <i>Journal of Pathology: Clinical Research</i> , 2017 , 3, 105-114	5.3	5
232	Prognostic significance of tumour infiltrating B lymphocytes in breast ductal carcinoma in situ. <i>Histopathology</i> , 2017 , 71, 258-268	7.3	36

231	Immunoprofile of metaplastic carcinomas of the breast. <i>Histopathology</i> , 2017 , 70, 975-985	7.3	39
230	DNA damage repair in breast cancer and its therapeutic implications. <i>Pathology</i> , 2017 , 49, 156-165	1.6	36
229	Molecular classification of breast cancer: what the pathologist needs to know. <i>Pathology</i> , 2017 , 49, 111-119	1.6	54
228	Reply to Rosen. <i>Modern Pathology</i> , 2017 , 30, 1505-1506	9.8	0
227	Rho-GTPase activating-protein 18: a biomarker associated with good prognosis in invasive breast cancer. <i>British Journal of Cancer</i> , 2017 , 117, 1176-1184	8.7	10
226	Novel immunohistochemistry-based signatures to predict metastatic site of triple-negative breast cancers. <i>British Journal of Cancer</i> , 2017 , 117, 826-834	8.7	7
225	The Spectrum of Triple-Negative Breast Disease: High- and Low-Grade Lesions. <i>American Journal of Pathology</i> , 2017 , 187, 2139-2151	5.8	78
224	An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation. <i>Breast Cancer Research</i> , 2017 , 19, 58	8.3	100
223	Caspase-3 and caspase-8 expression in breast cancer: caspase-3 is associated with survival. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2017 , 22, 357-368	5.4	85
222	Breast conservation in ductal carcinoma in situ (DCIS): what defines optimal margins?. <i>Histopathology</i> , 2017 , 70, 681-692	7.3	11
221	Clinicopathological and Functional Significance of RECQL1 Helicase in Sporadic Breast Cancers. <i>Molecular Cancer Therapeutics</i> , 2017 , 16, 239-250	6.1	12
220	Diagnostic concordance of breast pathologists: lessons from the National Health Service Breast Screening Programme Pathology External Quality Assurance Scheme. <i>Histopathology</i> , 2017 , 70, 632-642	7.3	14
219	Genetic analysis of microglandular adenosis and acinic cell carcinomas of the breast provides evidence for the existence of a low-grade triple-negative breast neoplasia family. <i>Modern Pathology</i> , 2017 , 30, 69-84	9.8	34
218	Further evidence to support bimodality of oestrogen receptor expression in breast cancer. <i>Histopathology</i> , 2017 , 70, 456-465	7.3	9
217	Grading of Invasive Carcinoma 2017 , 87-95		1
216	Current trials to reduce surgical intervention in ductal carcinoma in situ of the breast: Critical review. <i>Breast</i> , 2017 , 35, 151-156	3.6	21
215	Papillary Carcinomas 2017 , 137-152		1
214	Metaplastic Breast Carcinomas 2017 , 153-166		

213	Morphogenesis of the papillary lesions of the breast: phenotypic observation. <i>Journal of Clinical Pathology</i> , 2016 , 69, 64-9	3.9	7
212	Prognostic significance of androgen receptor expression in invasive breast cancer: transcriptomic and protein expression analysis. <i>Breast Cancer Research and Treatment</i> , 2016 , 159, 215-27	4.4	59
211	Clinicopathological and prognostic significance of mitogen-activated protein kinases (MAPK) in breast cancers. <i>Breast Cancer Research and Treatment</i> , 2016 , 159, 457-67	4.4	16
210	Invasive Lobular Carcinoma Mimicking Papillary Carcinoma: A Report of Three Cases. <i>Pathobiology</i> , 2016 , 83, 221-7	3.6	10
209	ADA3 regulates normal and tumor mammary epithelial cell proliferation through c-MYC. <i>Breast Cancer Research</i> , 2016 , 18, 113	8.3	7
208	RECQL4 helicase has oncogenic potential in sporadic breast cancers. <i>Journal of Pathology</i> , 2016 , 238, 495-501	9.4	29
207	Construction of tissue microarrays from core needle biopsies - a systematic literature review. <i>Histopathology</i> , 2016 , 68, 323-32	7.3	12
206	Imaging overview of metaplastic carcinomas of the breast: a large study of 71 cases. <i>British Journal of Radiology</i> , 2016 , 89, 20140644	3.4	14
205	Expression of CDK7, Cyclin H, and MAT1 Is Elevated in Breast Cancer and Is Prognostic in Estrogen Receptor-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 5929-5938	12.9	47
204	Bimodality of intratumor Ki67 expression is an independent prognostic factor of overall survival in patients with invasive breast carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016 , 468, 493-502	5.1	22
203	Clinical utility of reverse phase protein array for molecular classification of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016 , 155, 25-35	4.4	13
202	Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio-resistance in breast cancer. <i>Molecular Oncology</i> , 2016 , 10, 213-23	7.9	26
201	The prognostic significance of STAT3 in invasive breast cancer: analysis of protein and mRNA expressions in large cohorts. <i>Breast Cancer Research and Treatment</i> , 2016 , 156, 9-20	4.4	22
200	MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours. <i>British Journal of Cancer</i> , 2016 , 114, 917-28	8.7	64
199	Clinicopathological and prognostic significance of RECQL5 helicase expression in breast cancers. <i>Carcinogenesis</i> , 2016 , 37, 63-71	4.6	25
198	Potential of a novel technique for constructing tissue microarrays from core needle biopsy as seen in older women with primary breast cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e23283-e23283	2.2	
197	Multi-institutional study of triple negative breast cancer stratification by a metric that quantifies cell cycling kinetics.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1091-1091	2.2	
196	Identifying likely metastatic sites for triple negative breast cancers using immunohistochemical biomarkers.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1092-1092	2.2	

195	A combined HER3-EGFR score in triple-negative breast cancer: racial differences.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e12560-e12560	2.2	
194	A multi-institutional study of racial differences in androgen receptor status among triple-negative breast cancers.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1089-1089	2.2	0
193	Overexpression of Specific CD44 Isoforms Is Associated with Aggressive Cell Features in Acquired Endocrine Resistance. <i>Frontiers in Oncology</i> , 2016 , 6, 145	5.3	19
192	Papillary carcinoma of the breast: diagnostic agreement and management implications. <i>Histopathology</i> , 2016 , 69, 862-870	7.3	16
191	Infiltrating epitheliosis of the breast: characterization of histological features, immunophenotype and genomic profile. <i>Histopathology</i> , 2016 , 68, 1030-9	7.3	21
190	Microglandular adenosis associated with triple-negative breast cancer is a neoplastic lesion of triple-negative phenotype harbouring TP53 somatic mutations. <i>Journal of Pathology</i> , 2016 , 238, 677-88	9.4	42
189	Impact of intratumoural heterogeneity on the assessment of Ki67 expression in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016 , 158, 287-95	4.4	10
188	Pleomorphic adenoma-like tumour of the breast. <i>Histopathology</i> , 2016 , 68, 405-10	7.3	11
187	Human epidermal growth factor receptor 2 testing in invasive breast cancer: should histological grade, type and oestrogen receptor status influence the decision to repeat testing?. <i>Histopathology</i> , 2016 , 69, 20-4	7.3	6
186	Novel Immunohistochemical Based Biomarkers in Breast Cancer 2016 , 99-119		
185	Nottingham prognostic index plus (NPI+) predicts risk of distant metastases in primary breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016 , 157, 65-75	4.4	17
184	Nottingham Prognostic Index Plus: Validation of a clinical decision making tool in breast cancer in an independent series. <i>Journal of Pathology: Clinical Research</i> , 2016 , 2, 32-40	5.3	24
183	An approach to the diagnosis of spindle cell lesions of the breast. <i>Histopathology</i> , 2016 , 68, 33-44	7.3	41
182	Clinical and biological significance of RAD51 expression in breast cancer: a key DNA damage response protein. <i>Breast Cancer Research and Treatment</i> , 2016 , 159, 41-53	4.4	28
181	Breast lesions of uncertain malignant nature and limited metastatic potential: proposals to improve their recognition and clinical management. <i>Histopathology</i> , 2016 , 68, 45-56	7.3	29
180	Phyllodes tumours of the breast: a consensus review. <i>Histopathology</i> , 2016 , 68, 5-21	7.3	220
179	A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancer. <i>Molecular Oncology</i> , 2015 , 9, 115-27	7.9	35
178	Macroscopic handling and reporting of breast cancer specimens pre- and post-neoadjuvant chemotherapy treatment: review of pathological issues and suggested approaches. <i>Histopathology</i> , 2015 , 67, 279-93	7.3	21

177	Transcriptomic and Protein Expression Analysis Reveals Clinicopathological Significance of Bloom Syndrome Helicase (BLM) in Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 1057-65	6.1	32
176	Checkpoint kinase1 (CHK1) is an important biomarker in breast cancer having a role in chemotherapy response. <i>British Journal of Cancer</i> , 2015 , 112, 901-11	8.7	28
175	Updated UK Recommendations for HER2 assessment in breast cancer. <i>Journal of Clinical Pathology</i> , 2015 , 68, 93-9	3.9	155
174	KPNA2 is a nuclear export protein that contributes to aberrant localisation of key proteins and poor prognosis of breast cancer. <i>British Journal of Cancer</i> , 2015 , 112, 1929-37	8.7	43
173	Untangling the ATR-CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer. <i>Molecular Oncology</i> , 2015 , 9, 569-85	7.9	57
172	Prognostic and biological significance of peroxisome proliferator-activated receptor-gamma in luminal breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015 , 150, 511-22	4.4	17
171	Biological and clinical significance of PARP1 protein expression in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015 , 149, 353-62	4.4	48
170	DNA damage response markers are differentially expressed in BRCA-mutated breast cancers. <i>Breast Cancer Research and Treatment</i> , 2015 , 150, 81-90	4.4	30
169	The mammalian target of rapamycin complex 1 (mTORC1) in breast cancer: the impact of oestrogen receptor and HER2 pathways. <i>Breast Cancer Research and Treatment</i> , 2015 , 150, 91-103	4.4	10
168	Markers of progression in early-stage invasive breast cancer: a predictive immunohistochemical panel algorithm for distant recurrence risk stratification. <i>Breast Cancer Research and Treatment</i> , 2015 , 151, 325-33	4.4	20
167	Brief fixation and hormone receptor expression in breast cancer. <i>American Journal of Surgical Pathology</i> , 2015 , 39, 425	6.7	
166	Clinical and biological significance of glucocorticoid receptor (GR) expression in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015 , 150, 335-46	4.4	59
165	Molecular Pathology of Precancerous Lesions of the Breast. <i>Molecular Pathology Library</i> , 2015 , 51-62		1
164	Stratification of resectable lung adenocarcinoma by molecular and pathological risk estimators. <i>European Journal of Cancer</i> , 2015 , 51, 1897-903	7.5	10
163	National guidelines and level of evidence: comments on some of the new recommendations in the American Society of Clinical Oncology and the College of American Pathologists human epidermal growth factor receptor 2 guidelines for breast cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1301-2	2.2	28
162	Molecular Classification of Breast Cancer. <i>Molecular Pathology Library</i> , 2015 , 137-155		
161	Molecular Pathology of Hormone Regulation in Breast Cancer: Hormone Receptor Evaluation and Therapeutic Implications. <i>Molecular Pathology Library</i> , 2015 , 107-118		
160	Prognostic factors in metaplastic carcinoma of the breast: a multi-institutional study. <i>British Journal of Cancer</i> , 2015 , 112, 283-9	8.7	67

159	Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy. <i>Molecular Oncology</i> , 2015 , 9, 204-17	7.9	55
158	The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesis-generating study. <i>Journal of Pathology</i> , 2015 , 237, 166-78	9.4	42
157	Are acinic cell carcinomas of the breast and salivary glands distinct diseases?. <i>Histopathology</i> , 2015 , 67, 529-37	7.3	25
156	A case-controlled study of the oncologic safety of fat grafting. <i>Plastic and Reconstructive Surgery</i> , 2015 , 135, 1263-1275	2.7	87
155	High-grade encapsulated papillary carcinoma of the breast: an under-recognized entity. <i>Histopathology</i> , 2015 , 66, 740-6	7.3	36
154	Inflammatory breast cancer: time to standardise diagnosis assessment and management, and for the joining of forces to facilitate effective research. <i>British Journal of Cancer</i> , 2015 , 112, 1613-5	8.7	28
153	Molecular-Based Diagnostic, Prognostic and Predictive Tests in Breast Cancer. <i>Molecular Pathology Library</i> , 2015 , 177-195		1
152	Molecular Pathology of Breast Cancer Metastasis. <i>Molecular Pathology Library</i> , 2015 , 271-289		1
151	Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents. <i>Breast Cancer Research</i> , 2015 , 17, 59	8.3	42
150	Molecular Mechanisms Underlying Lymphovascular Invasion in Invasive Breast Cancer. <i>Pathobiology</i> , 2015 , 82, 113-23	3.6	37
149	Breast Neoplasms with Dermal Analogue Differentiation (Mammary Cylindroma): Report of 3 Cases and a Proposal for a New Terminology. <i>Pathobiology</i> , 2015 , 82, 172-8	3.6	2
148	FKBPL: a marker of good prognosis in breast cancer. <i>Oncotarget</i> , 2015 , 6, 12209-23	3.3	9
147	DNA repair prognostic index modelling reveals an essential role for base excision repair in influencing clinical outcomes in ER negative and triple negative breast cancers. <i>Oncotarget</i> , 2015 , 6, 21964-78	3.3	17
146	The pioneer factor PBX1 is a novel driver of metastatic progression in ER β -positive breast cancer. <i>Oncotarget</i> , 2015 , 6, 21878-91	3.3	28
145	Characterisation of HER heterodimers in breast cancer using in situ proximity ligation assay. <i>Breast Cancer Research and Treatment</i> , 2014 , 144, 273-85	4.4	14
144	SUMOylation proteins in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014 , 144, 519-30	4.4	26
143	The updated ASCO/CAP guideline recommendations for HER2 testing in the management of invasive breast cancer: a critical review of their implications for routine practice. <i>Histopathology</i> , 2014 , 64, 609-15	7.3	55
142	Epithelial mesenchymal transition in early invasive breast cancer: an immunohistochemical and reverse phase protein array study. <i>Breast Cancer Research and Treatment</i> , 2014 , 145, 339-48	4.4	44

141	C-Met in invasive breast cancer: is there a relationship with the basal-like subtype?. <i>Cancer</i> , 2014 , 120, 163-71	6.4	38
140	Adverse prognostic and predictive significance of low DNA-dependent protein kinase catalytic subunit (DNA-PKcs) expression in early-stage breast cancers. <i>Breast Cancer Research and Treatment</i> , 2014 , 146, 309-20	4.4	10
139	ERK1/2 is related to oestrogen receptor and predicts outcome in hormone-treated breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014 , 147, 25-37	4.4	13
138	HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014 , 145, 33-44	4.4	26
137	Prognostic and biological significance of proliferation and HER2 expression in the luminal class of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014 , 145, 317-30	4.4	10
136	Towards intra-operative diagnosis of tumours during breast conserving surgery by selective-sampling Raman micro-spectroscopy. <i>Physics in Medicine and Biology</i> , 2014 , 59, 6141-52	3.8	67
135	PIAS1 expression in relation to clinicopathological, tumour factors and survival in indigenous black breast cancer women. <i>Journal of Clinical Pathology</i> , 2014 , 67, 301-6	3.9	9
134	Nottingham Prognostic Index Plus (NPI+): a modern clinical decision making tool in breast cancer. <i>British Journal of Cancer</i> , 2014 , 110, 1688-97	8.7	68
133	Clinicopathological significance of ATM-Chk2 expression in sporadic breast cancers: a comprehensive analysis in large cohorts. <i>Neoplasia</i> , 2014 , 16, 982-91	6.4	30
132	Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. <i>Annals of Oncology</i> , 2014 , 25, 1536-43	10.3	433
131	Inclusion of KI67 significantly improves performance of the PREDICT prognostication and prediction model for early breast cancer. <i>BMC Cancer</i> , 2014 , 14, 908	4.8	33
130	Low calpain-9 is associated with adverse disease-specific survival following endocrine therapy in breast cancer. <i>BMC Cancer</i> , 2014 , 14, 995	4.8	14
129	Involvement of metformin and AMPK in the radioresponse and prognosis of luminal versus basal-like breast cancer treated with radiotherapy. <i>Oncotarget</i> , 2014 , 5, 12936-49	3.3	39
128	Predicting chemotherapy response in invasive breast cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1084-1084		
127	Pathology and biology of breast cancer 2014 , 20-43		
126	Molecular profiling of breast cancer in Nigerian women identifies an altered p53 pathway as a major mechanism underlying its poor prognosis compared with British counterpart. <i>Malaysian Journal of Pathology</i> , 2014 , 36, 3-17	1.7	5
125	Identification of key clinical phenotypes of breast cancer using a reduced panel of protein biomarkers. <i>British Journal of Cancer</i> , 2013 , 109, 1886-94	8.7	34
124	Pitfalls in outcome prediction of breast cancer. <i>Journal of Clinical Pathology</i> , 2013 , 66, 458-64	3.9	26

123	Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. <i>Breast Cancer Research</i> , 2013 , 15, R92	8.3	248
122	The oestrogen receptor coactivator CARM1 has an oncogenic effect and is associated with poor prognosis in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013 , 140, 307-16	4.4	34
121	Clinicopathological significance of KU70/KU80, a key DNA damage repair protein in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013 , 139, 301-10	4.4	46
120	AuthorsPreply: Combining two antibodies to define E-cadherin loss of expression in non-lobular breast carcinomas: when less is more. <i>Histopathology</i> , 2013 , 63, 440-3	7.3	
119	Outcome of pure mucocele-like lesions diagnosed on breast core biopsy. <i>Histopathology</i> , 2013 , 62, 894-897	7.3	37
118	Targeting XRCC1 deficiency in breast cancer for personalized therapy. <i>Cancer Research</i> , 2013 , 73, 1621-34	10.1	71
117	Lack of expression of the proteins GMPR2 and PPAR α are associated with the basal phenotype and patient outcome in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013 , 137, 127-37	4.4	15
116	The microRNA maturation regulator Drosha is an independent predictor of outcome in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2013 , 137, 139-53	4.4	17
115	Cytoplasmic localization of alteration/deficiency in activation 3 (ADA3) predicts poor clinical outcome in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2013 , 137, 721-31	4.4	13
114	Characteristics of basal cytokeratin expression in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013 , 139, 23-37	4.4	28
113	Further evidence that E-cadherin is not a tumour suppressor gene in invasive ductal carcinoma of the breast: an immunohistochemical study. <i>Histopathology</i> , 2013 , 62, 695-701	7.3	23
112	Do primary mammary osteosarcoma and chondrosarcoma exist? A review of a large multi-institutional series of malignant matrix-producing breast tumours. <i>Breast</i> , 2013 , 22, 13-8	3.6	34
111	Pleomorphic lobular carcinoma of the breast: is it a prognostically significant pathological subtype independent of histological grade?. <i>Modern Pathology</i> , 2013 , 26, 496-501	9.8	33
110	Cell Proliferation (KI-67) Expression Is Associated with Poorer Prognosis in Nigerian Compared to British Breast Cancer Women. <i>ISRN Oncology</i> , 2013 , 2013, 675051		11
109	Lobular neoplasia of the breast revisited with emphasis on the role of E-cadherin immunohistochemistry. <i>American Journal of Surgical Pathology</i> , 2013 , 37, e1-11	6.7	109
108	Histological risk factors, prognostic indicators and staging 2013 , 236-249		
107	Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer. <i>Breast Cancer Research</i> , 2012 , 14, R3	8.3	94
106	Loss of Dicer expression is associated with breast cancer progression and recurrence. <i>Breast Cancer Research and Treatment</i> , 2012 , 135, 403-13	4.4	69

105	Molecular characteristics and prognostic features of breast cancer in Nigerian compared with UK women. <i>Breast Cancer Research and Treatment</i> , 2012 , 135, 555-69	4.4	38
104	TOMM34 expression in early invasive breast cancer: a biomarker associated with poor outcome. <i>Breast Cancer Research and Treatment</i> , 2012 , 136, 419-27	4.4	20
103	Phyllodes Tumor of the Breast 2012 , 243-256		2
102	The low nuclear grade breast neoplasia family. <i>Diagnostic Histopathology</i> , 2012 , 18, 124-132	0.7	8
101	The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. <i>Nature</i> , 2012 , 486, 346-52	50.4	3479
100	The prognostic significance of lymphovascular invasion in invasive breast carcinoma. <i>Cancer</i> , 2012 , 118, 3670-80	6.4	145
99	Fatty acid binding protein 7 expression and its sub-cellular localization in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012 , 134, 519-29	4.4	20
98	EpCAM expression is an indicator of recurrence in basal-like breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012 , 133, 575-82	4.4	20
97	A CD44 ⁺ /CD24 ⁺ phenotype is a poor prognostic marker in early invasive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012 , 133, 979-95	4.4	79
96	Overexpression of a novel cell cycle regulator ecdysoneless in breast cancer: a marker of poor prognosis in HER2/neu-overexpressing breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2012 , 134, 171-80	4.4	16
95	A review of the biological and clinical characteristics of luminal-like oestrogen receptor-positive breast cancer. <i>Histopathology</i> , 2012 , 60, 854-63	7.3	18
94	Re-audit of revised method for assessing the mitotic component of histological grade in needle core biopsies of invasive carcinoma of the breast. <i>Histopathology</i> , 2012 , 60, 1166-7	7.3	3
93	Encapsulated papillary carcinoma of the breast: a study of invasion associated markers. <i>Journal of Clinical Pathology</i> , 2012 , 65, 710-4	3.9	33
92	Efficacy of an incident-reporting system in cellular pathology: a practical experience. <i>Journal of Clinical Pathology</i> , 2012 , 65, 643-8	3.9	3
91	Infiltrative epitheliosis of the breast. <i>Journal of Clinical Pathology</i> , 2012 , 65, 766-8	3.9	8
90	The prognostic significance of early stage lymph node positivity in operable invasive breast carcinoma: number or stage. <i>Journal of Clinical Pathology</i> , 2012 , 65, 624-30	3.9	9
89	Integrating breast cancer genetics into clinical practice. <i>Women's Health</i> , 2012 , 8, 99-112	3	4
88	PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2. <i>British Journal of Cancer</i> , 2012 , 107, 800-7	8.7	130

87	The value of examination of multiple levels of mammary needle core biopsy specimens taken for investigation of lesions other than calcification. <i>Journal of Clinical Pathology</i> , 2012 , 65, 1097-9	3.9	8
86	Low-estrogen receptor-positive breast cancer: the impact of tissue sampling, choice of antibody, and molecular subtyping. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2929-30; author reply 2931	2.2	13
85	Clinical outcome of atypical endometrial hyperplasia diagnosed on an endometrial biopsy: institutional experience and review of literature. <i>American Journal of Surgical Pathology</i> , 2012 , 36, 1683-90	6.7	52
84	Modern classification of breast cancer: should we stick with morphology or convert to molecular profile characteristics. <i>Advances in Anatomic Pathology</i> , 2011 , 18, 255-67	5.1	53
83	Encapsulated papillary carcinoma of the breast: an invasive tumor with excellent prognosis. <i>American Journal of Surgical Pathology</i> , 2011 , 35, 1093-103	6.7	95
82	Outcome of breast lesions diagnosed as lesion of uncertain malignant potential (B3) or suspicious of malignancy (B4) on needle core biopsy, including detailed review of epithelial atypia. <i>Histopathology</i> , 2011 , 58, 626-32	7.3	49
81	Histological grade of invasive carcinoma of the breast assessed on needle core biopsy - modifications to mitotic count assessment to improve agreement with surgical specimens. <i>Histopathology</i> , 2011 , 59, 543-8	7.3	21
80	Metastatic triple-negative breast cancer. <i>Clinical Oncology</i> , 2011 , 23, 587-600	2.8	81
79	Clinicopathologic and molecular significance of phospho-Akt expression in early invasive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011 , 127, 407-16	4.4	45
78	MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups. <i>Breast Cancer Research and Treatment</i> , 2011 , 127, 591-9	4.4	82
77	RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype. <i>Breast Cancer Research and Treatment</i> , 2011 , 128, 315-26	4.4	33
76	FOXO3a nuclear localisation is associated with good prognosis in luminal-like breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011 , 129, 11-21	4.4	59
75	Metaplastic breast carcinoma: tumour histogenesis or dedifferentiation?. <i>Journal of Pathology</i> , 2011 , 224, 434-7	9.4	35
74	The impact of using defined criteria for adequacy of fine needle aspiration cytology of the thyroid in routine practice. <i>Diagnostic Cytopathology</i> , 2011 , 39, 81-6	1.4	18
73	Characterization and outcome of breast needle core biopsy diagnoses of lesions of uncertain malignant potential (B3) in abnormalities detected by mammographic screening. <i>International Journal of Cancer</i> , 2011 , 129, 1417-24	7.5	70
72	Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. <i>Modern Pathology</i> , 2011 , 24, 157-67	9.8	447
71	Lymphatic and blood vessels in basal and triple-negative breast cancers: characteristics and prognostic significance. <i>Modern Pathology</i> , 2011 , 24, 774-85	9.8	84
70	Lymph-node metastases in invasive lobular carcinoma are different from those in ductal carcinoma of the breast. <i>Journal of Clinical Pathology</i> , 2011 , 64, 995-1000	3.9	34

69	Histological grading of breast cancer on needle core biopsy: the role of immunohistochemical assessment of proliferation. <i>Histopathology</i> , 2010 , 57, 212-9	7.3	32
68	Cytological assessment of conventional transbronchial fine needle aspiration of lymph nodes. <i>Cytopathology</i> , 2010 , 21, 27-34	1.3	10
67	Topo2 β protein expression predicts response to anthracycline combination neo-adjuvant chemotherapy in locally advanced primary breast cancer. <i>British Journal of Cancer</i> , 2010 , 103, 1794-800	8.7	21
66	Evaluation of touch preparation cytology during frozen-section diagnoses of pulmonary lesions. <i>Journal of Clinical Pathology</i> , 2010 , 63, 675-7	3.9	8
65	Tubular carcinoma of the breast: further evidence to support its excellent prognosis. <i>Journal of Clinical Oncology</i> , 2010 , 28, 99-104	2.2	129
64	Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. <i>PLoS Medicine</i> , 2010 , 7, e1000279	11.6	616
63	Histological features of medullary carcinoma and prognosis in triple-negative basal-like carcinomas of the breast. <i>Modern Pathology</i> , 2010 , 23, 1357-63	9.8	43
62	Portal inflammation is associated with advanced histological changes in alcoholic and non-alcoholic fatty liver disease. <i>Journal of Clinical Pathology</i> , 2010 , 63, 790-5	3.9	35
61	Screen-detected malignant breast lesions diagnosed following benign (B2) or normal (B1) needle core biopsy diagnoses. <i>European Journal of Cancer</i> , 2010 , 46, 1835-40	7.5	6
60	Lobular breast carcinoma and its variants. <i>Seminars in Diagnostic Pathology</i> , 2010 , 27, 49-61	4.3	95
59	Breast cancer prognostic classification in the molecular era: the role of histological grade. <i>Breast Cancer Research</i> , 2010 , 12, 207	8.3	459
58	Clinical and biological significance of E-cadherin protein expression in invasive lobular carcinoma of the breast. <i>American Journal of Surgical Pathology</i> , 2010 , 34, 1472-9	6.7	110
57	Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen. <i>Breast Cancer Research and Treatment</i> , 2010 , 119, 283-93	4.4	155
56	A validated gene expression profile for detecting clinical outcome in breast cancer using artificial neural networks. <i>Breast Cancer Research and Treatment</i> , 2010 , 120, 83-93	4.4	47
55	The prognostic significance of PELP1 expression in invasive breast cancer with emphasis on the ER-positive luminal-like subtype. <i>Breast Cancer Research and Treatment</i> , 2010 , 120, 603-12	4.4	66
54	The proteins FABP7 and OATP2 are associated with the basal phenotype and patient outcome in human breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010 , 121, 41-51	4.4	43
53	PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis. <i>Breast Cancer Research and Treatment</i> , 2010 , 122, 45-53	4.4	63
52	Combinatorial biomarker expression in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010 , 120, 293-308	4.4	150

51	Growth fraction as a predictor of response to chemotherapy in node-negative breast cancer. <i>International Journal of Cancer</i> , 2010 , 126, 1761-9	7.5	29
50	The sensitivity of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. <i>Diagnostic Cytopathology</i> , 2010 , 38, 874-9	1.4	57
49	A methodology to identify consensus classes from clustering algorithms applied to immunohistochemical data from breast cancer patients. <i>Computers in Biology and Medicine</i> , 2010 , 40, 318-30	7	42
48	Influence of E-cadherin expression on the mammographic appearance of invasive nonlobular breast carcinoma detected at screening. <i>Radiology</i> , 2009 , 253, 51-5	20.5	11
47	Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. <i>Cancer Research</i> , 2009 , 69, 3802-9	10.1	340
46	The biological and clinical characteristics of breast carcinoma with mixed ductal and lobular morphology. <i>Breast Cancer Research and Treatment</i> , 2009 , 114, 243-50	4.4	38
45	Tumor size is an unreliable predictor of prognosis in basal-like breast cancers and does not correlate closely with lymph node status. <i>Breast Cancer Research and Treatment</i> , 2009 , 117, 199-204	4.4	69
44	Loss of expression of chromosome 16q genes DPEP1 and CTCF in lobular carcinoma in situ of the breast. <i>Breast Cancer Research and Treatment</i> , 2009 , 113, 59-66	4.4	42
43	Patho-biological aspects of basal-like breast cancer. <i>Breast Cancer Research and Treatment</i> , 2009 , 113, 411-22	4.4	61
42	The expression of ERalpha, ERbeta and PR in lobular carcinoma in situ of the breast determined using laser microdissection and real-time PCR. <i>Histopathology</i> , 2009 , 54, 419-27	7.3	9
41	Sonographic correlations with the new molecular classification of invasive breast cancer. <i>European Radiology</i> , 2009 , 19, 2342-8	8	48
40	Screen-detected breast lesions with malignant needle core biopsy diagnoses and no malignancy identified in subsequent surgical excision specimens (potential false-positive diagnosis). <i>European Journal of Cancer</i> , 2009 , 45, 1162-1167	7.5	17
39	Triple-negative/basal-like breast cancer: review. <i>Pathology</i> , 2009 , 41, 40-7	1.6	204
38	Investigating AP-2 and YY1 protein expression as a cause of high HER2 gene transcription in breast cancers with discordant HER2 gene amplification. <i>Breast Cancer Research</i> , 2009 , 11, R90	8.3	37
37	Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. <i>Clinical Cancer Research</i> , 2009 , 15, 2302-10	12.9	371
36	Basal-like breast carcinoma: from expression profiling to routine practice. <i>Archives of Pathology and Laboratory Medicine</i> , 2009 , 133, 860-8	5	58
35	Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas). <i>Modern Pathology</i> , 2008 , 21, 1060-1; author reply 1061-2	9.8	10
34	Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype. <i>British Journal of Cancer</i> , 2008 , 99, 327-34	8.7	122

33	Predictive value of needle core biopsy diagnoses of lesions of uncertain malignant potential (B3) in abnormalities detected by mammographic screening. <i>Histopathology</i> , 2008 , 53, 650-7	7.3	113
32	Vacuum-assisted excision of breast lesions of uncertain malignant potential (B3) - an alternative to surgery in selected cases. <i>Breast</i> , 2008 , 17, 546-9	3.6	35
31	Expression of BRCA1 protein in breast cancer and its prognostic significance. <i>Human Pathology</i> , 2008 , 39, 857-65	3.7	115
30	Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes. <i>European Journal of Cancer</i> , 2008 , 44, 73-83	7.5	164
29	Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance. <i>European Journal of Cancer</i> , 2008 , 44, 1541-51	7.5	74
28	Audit of performance of needle core biopsy diagnoses of screen detected breast lesions. <i>European Journal of Cancer</i> , 2008 , 44, 2580-6	7.5	28
27	The mammographic correlations of a new immunohistochemical classification of invasive breast cancer. <i>Clinical Radiology</i> , 2008 , 63, 1228-35	2.9	22
26	Basal-like breast cancer: a critical review. <i>Journal of Clinical Oncology</i> , 2008 , 26, 2568-81	2.2	657
25	Breast carcinoma with basal phenotype: mammographic findings. <i>American Journal of Roentgenology</i> , 2008 , 191, 346-51	5.4	36
24	Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. <i>Journal of Clinical Oncology</i> , 2008 , 26, 3153-8	2.2	336
23	Are triple-negative and basal-like breast cancer synonymous?. <i>Clinical Cancer Research</i> , 2008 , 14, 618; author reply 618-9	12.9	42
22	Impact of basal-like breast carcinoma determination for a more specific therapy. <i>Pathobiology</i> , 2008 , 75, 95-103	3.6	25
21	Expression profiling technology: its contribution to our understanding of breast cancer. <i>Histopathology</i> , 2008 , 52, 67-81	7.3	34
20	The prognostic significance of steroid receptor co-regulators in breast cancer: co-repressor NCOR2/SMRT is an independent indicator of poor outcome. <i>Breast Cancer Research and Treatment</i> , 2008 , 110, 427-37	4.4	49
19	Histologic grading is an independent prognostic factor in invasive lobular carcinoma of the breast. <i>Breast Cancer Research and Treatment</i> , 2008 , 111, 121-7	4.4	96
18	The p53 positive Bcl-2 negative phenotype is an independent marker of prognosis in breast cancer. <i>International Journal of Cancer</i> , 2007 , 120, 1311-7	7.5	34
17	Prognostic markers in triple-negative breast cancer. <i>Cancer</i> , 2007 , 109, 25-32	6.4	963
16	Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression. <i>Histopathology</i> , 2007 , 50, 434-8	7.3	132

15	Gigantic recurrent abdominal desmoid tumour: a case report. <i>Hernia: the Journal of Hernias and Abdominal Wall Surgery</i> , 2007 , 11, 193-7	3.2	6
14	Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4772-8	2.2	213
13	Basal phenotype: a powerful prognostic factor in small screen-detected invasive breast cancer with long-term follow-up. <i>Journal of Medical Screening</i> , 2007 , 14, 210-4	1.4	21
12	Are triple-negative tumours and basal-like breast cancer synonymous?. <i>Breast Cancer Research</i> , 2007 , 9, 404; author reply 405	8.3	83
11	Are triple negative tumours and basal-like breast cancer synonymous?. <i>Breast Cancer Research</i> , 2007 , 9, R80	8.3	6
10	Chromosome 16 tumor-suppressor genes in breast cancer. <i>Genes Chromosomes and Cancer</i> , 2006 , 45, 527-35	5	69
9	Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. <i>European Journal of Cancer</i> , 2006 , 42, 3149-56	7.5	164
8	E-cadherin expression in invasive non-lobular carcinoma of the breast and its prognostic significance. <i>Histopathology</i> , 2005 , 46, 685-93	7.3	132
7	Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. <i>Modern Pathology</i> , 2005 , 18, 26-35	9.8	196
6	Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. <i>Modern Pathology</i> , 2005 , 18, 1295-304	9.8	257
5	High-resolution analysis of 16q22.1 in breast carcinoma using DNA amplifiable probes (multiplex amplifiable probe hybridization technique) and immunohistochemistry. <i>International Journal of Cancer</i> , 2005 , 114, 720-9	7.5	18
4	High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. <i>International Journal of Cancer</i> , 2005 , 116, 340-50	7.5	443
3	Expression of the transcription factor CTCF in invasive breast cancer: a candidate gene located at 16q22.1. <i>British Journal of Cancer</i> , 2004 , 91, 1591-6	8.7	28
2	Expression of E2F-4 in invasive breast carcinomas is associated with poor prognosis. <i>Journal of Pathology</i> , 2004 , 203, 754-61	9.4	33
1	Artificial Intelligence for Advance Requesting of Immunohistochemistry in Diagnostically Uncertain Prostate Biopsies		1